French Public Authorities and Government Agencies
ANSM – Agence Nationale de Sécurité des Médicaments et des Produits de Santé (National Agency for the Safety of Drugs and Health Products) Key People: Dominique Martin, CEO The National Agency…
Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Conscious of the importance of strategically aligning our company with patient needs, our R&D efforts are focused on contributing to bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent.Our rigorous drug discovery and development process, and our commitment to improving health through innovation, have resulted in the creation of a pipeline dedicated to areas where we can lead and make a significant impact.
Our lead pipeline product Elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis) and is currently launching a Phase 3 study. This metabolism-related liver disease, which can progress to cirrhosis and even liver cancer, shows a dramatically increasing prevalence worldwide. Elafibranor represents a major hope for patients and their physicians, who currently have no efficient treatment for NASH.
In addition to Elafibranor, our R&D pipeline relies mainly on our world-renowned scientific expertise in gene regulation and nuclear receptors.
It is comprised of multiple drug candidate research programs targeting novel mechanisms of action including the inhibition of RORγ-t.
GENFIT Headquarters
Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos
France
+33 (0)3 20 16 40 00
ANSM – Agence Nationale de Sécurité des Médicaments et des Produits de Santé (National Agency for the Safety of Drugs and Health Products) Key People: Dominique Martin, CEO The National Agency…
Marc Julien, co-CEO of Diabeloop, presents the revolutionary “artificial pancreas” the company has developed to support type one diabetes patients. The device embeds artificial intelligence to help type one diabetics…
Vincent Poher, founder of Avalun, explains the key technology behind the establishment of the company as well as their forthcoming expansion strategy. He also outlines the main challenges start-ups can…
In an exclusive interview, Yves L’Epine, president of G5 Santé and CEO of Guerbet, offers his insider take on the business climate in French healthcare and the potential for France…
INCa – Institut National du Cancer (The National Cancer Institute) The National Cancer Institute (INCa) is the state agency of health and scientific expertise in oncology in…
DSS Direction de la Sécurité (Department of Social Security) Key People: Director General Mathilde Lignot-Leloup The Directorate of Social Security (DSS) supervises all social security organizations: general scheme funds,…
Commission des Affaires Sociales de l’Assemblée Nationale (Commission of Social Affairs, National Assembly) Key People: Brigitte Bourguignon, Chairwoman Olivier Véran, General Reporter The Social Affairs Committee of the National Assembly is…
Joël Jaouen, president of France Alzheimer, provides important insights into the role and objectives of the patient association. He explains why France Alzheimer together with other learned societies filed a…
PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in French pharma’s industry, regulatory affairs, reimbursement and pricing. Maurice-Pierre Planel — President of CEPS Maurice-Pierre Planel Has been…
Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience. We are…
Gérard Raymond, president of the Fédération Francaise des Diabétiques (FFD – French Diabetes Federation), gives an update on the situation of diabetes in France and explains the challenges for patient…
Christophe Cizeron, president of Lyonbiopole, discusses the important economic and industrial position of the research cluster in the Rhone-Alps Region as well as the challenges posed by domestic and international…
See our Cookie Privacy Policy Here
